GSA Capital Partners’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
Other funds holding XLO
GSA Capital Partners's XLO Position: Q3 2026 in Review
GSA Capital Partners increased its Xilio Therapeutics (XLO) stake by 23% in Q3 2026, buying an estimated $27.9K and bringing the position to 16,673 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #1654.
GSA Capital Partners first reported a position in XLO in Q4 2025 and has held it in 4 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.
- GSA Capital Partners held 16,673 shares of Xilio Therapeutics worth $151K as of Q3 2026.
- GSA Capital Partners bought 3,083 Xilio Therapeutics shares in Q3 2026, an estimated $27.9K.
- Xilio Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1654 holding.
- GSA Capital Partners first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.